Foghorn Therapeutics: Guggenheim cuts target price to $5 from $12
FHTX•Guggenheim cut its target price for Foghorn Therapeutics to $5 from $12.
Related News
CleanSpark CTO, COO Taylor Monnig disposes of 16,458 common shares worth $202,972
CLSK•
Moderna to replace Warner Bros. Discovery on Nasdaq 100
MRNA•
Levi Strauss & Co: Raymond James cuts target price to $24 from $27
LEVI•
Abogen Biosciences signs licensing, option deal with Novartis for ABO2203 mRNA T-cell engager
NVS•
Ceribell, Inc.: TD Cowen raises target price to $33 from $29
CBLL•